Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lucas Moreno

Showing results (71-80 of 122) with videos related to

Pageof 13
Sort By:
Pediatric Blood & Cancer|November 18, 2020
A nomogram of clinical and biologic factors to predict survival in children newly diagnosed with high-risk neuroblastoma: An International Neuroblastoma Risk Group projectLucas Moreno, Dongjing Guo, Meredith S Irwin, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|February 25, 2025
Management and outcome of children with high-risk neuroblastoma: insights from the Spanish Society of Pediatric Hematology and Oncology (SEHOP) neuroblastoma group on refractory and relapse/progressive diseaseBlanca Martínez de Las Heras, Pedro M Rubio-Aparicio, Alba Rubio-San-Simón, et al.
The Lancet. Oncology|November 15, 2021
Ceritinib in paediatric patients with anaplastic lymphoma kinase-positive malignancies: an open-label, multicentre, phase 1, dose-escalation and dose-expansion studyMatthias Fischer, Lucas Moreno, David S Ziegler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 14, 2024
Evolution of the Innovative Therapies for Children With Cancer Consortium Trial Portfolio for Drug Development for Children With CancerFrancisco Bautista, Jaime Verdú-Amorós, Birgit Geoerger, et al.
Cancers|July 26, 2020
CN133, a Novel Brain-Penetrating Histone Deacetylase Inhibitor, Hampers Tumor Growth in Patient-Derived Pediatric Posterior Fossa Ependymoma ModelsRoberta Antonelli, Carlos Jiménez, Misha Riley, et al.
Cancers|October 13, 2021
Neuronal Differentiation-Related Epigenetic Regulator <i>ZRF1</i> Has Independent Prognostic Value in Neuroblastoma but Is Functionally Dispensable In VitroCarlos Jiménez, Roberta Antonelli, Marc Masanas, et al.
Cancer|September 14, 2022
Early-phase clinical trial eligibility and response evaluation criteria for refractory, relapsed, or progressive neuroblastoma: A consensus statement from the National Cancer Institute Clinical Trials Planning MeetingJulie R Park, Judith G Villablanca, Barbara Hero, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|April 8, 2025
A comprehensive clinico-pathological review of a series of pediatric, adolescents and young adults with high-grade osteosarcoma: from clinics to biomarker discoverySusana Buendía-López, Alba Rubio-San-Simón, Jen-Hao Wu, et al.
Experimental Hematology & Oncology|April 5, 2024
TRIB3 silencing promotes the downregulation of Akt pathway and PAX3-FOXO1 in high-risk rhabdomyosarcomaGabriel Gallo-Oller, Guillem Pons, Júlia Sansa-Girona, et al.
Journal of Neuro-Oncology|December 14, 2017
Outcome of children and adolescents with central nervous system tumors in phase I trialsFernando Carceller, Francisco Bautista, Irene Jiménez, et al.
Pageof 13

Showing results (71-80 of 122) with videos related to

Sort By:
Pageof 13
Pediatric Blood & Cancer|November 18, 2020
A nomogram of clinical and biologic factors to predict survival in children newly diagnosed with high-risk neuroblastoma: An International Neuroblastoma Risk Group projectLucas Moreno, Dongjing Guo, Meredith S Irwin, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|February 25, 2025
Management and outcome of children with high-risk neuroblastoma: insights from the Spanish Society of Pediatric Hematology and Oncology (SEHOP) neuroblastoma group on refractory and relapse/progressive diseaseBlanca Martínez de Las Heras, Pedro M Rubio-Aparicio, Alba Rubio-San-Simón, et al.
The Lancet. Oncology|November 15, 2021
Ceritinib in paediatric patients with anaplastic lymphoma kinase-positive malignancies: an open-label, multicentre, phase 1, dose-escalation and dose-expansion studyMatthias Fischer, Lucas Moreno, David S Ziegler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 14, 2024
Evolution of the Innovative Therapies for Children With Cancer Consortium Trial Portfolio for Drug Development for Children With CancerFrancisco Bautista, Jaime Verdú-Amorós, Birgit Geoerger, et al.
Cancers|July 26, 2020
CN133, a Novel Brain-Penetrating Histone Deacetylase Inhibitor, Hampers Tumor Growth in Patient-Derived Pediatric Posterior Fossa Ependymoma ModelsRoberta Antonelli, Carlos Jiménez, Misha Riley, et al.
Cancers|October 13, 2021
Neuronal Differentiation-Related Epigenetic Regulator <i>ZRF1</i> Has Independent Prognostic Value in Neuroblastoma but Is Functionally Dispensable In VitroCarlos Jiménez, Roberta Antonelli, Marc Masanas, et al.
Cancer|September 14, 2022
Early-phase clinical trial eligibility and response evaluation criteria for refractory, relapsed, or progressive neuroblastoma: A consensus statement from the National Cancer Institute Clinical Trials Planning MeetingJulie R Park, Judith G Villablanca, Barbara Hero, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|April 8, 2025
A comprehensive clinico-pathological review of a series of pediatric, adolescents and young adults with high-grade osteosarcoma: from clinics to biomarker discoverySusana Buendía-López, Alba Rubio-San-Simón, Jen-Hao Wu, et al.
Experimental Hematology & Oncology|April 5, 2024
TRIB3 silencing promotes the downregulation of Akt pathway and PAX3-FOXO1 in high-risk rhabdomyosarcomaGabriel Gallo-Oller, Guillem Pons, Júlia Sansa-Girona, et al.
Journal of Neuro-Oncology|December 14, 2017
Outcome of children and adolescents with central nervous system tumors in phase I trialsFernando Carceller, Francisco Bautista, Irene Jiménez, et al.
Pageof 13